Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10354-016-0503-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intratumoral Injection of Engineered Induces Antitumor Immunity and Inhibits Tumor Growth.
Biomater Res
January 2024
The Comprehensive Cancer Centre, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
Conventional type 1 dendritic cells are essential for antigen presentation and successful initiation of antitumor CD8 T cells. However, their abundance and function within tumors tend to be limited. , a fast-growing, nonpathogenic mycobacterium, proves to be easily modified with synthetic biology.
View Article and Find Full Text PDFMelanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
J Clin Oncol
January 2025
Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN.
Purpose: Melanoma as a subsequent malignant neoplasm has been described among childhood cancer survivors; however, the risk factors and long-term survival are not well understood.
Methods: We assessed incidence, risk factors, and outcomes for melanoma among participants in the Childhood Cancer Survivor Study cohort. Cumulative incidence and standardized incidence ratios (SIRs) were calculated, and multivariable Cox models were used to determine hazard ratios (HRs) and associated 95% CI for melanoma risk factors.
Anti-PD-1 amplifies costimulation in melanoma-infiltrating T1-like Foxp3 regulatory T cells to alleviate local immunosuppression.
J Immunother Cancer
January 2025
Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada
Background: Immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) are the first line of treatment for many solid tumors including melanoma. PD-1 blockade enhances the effector functions of melanoma-infiltrating CD8 T cells, leading to durable tumor remissions. However, 55% of patients with melanoma do not respond to treatment.
View Article and Find Full Text PDFLocal Control of Conjunctival Malignant Melanoma by Proton Beam Therapy in a Patient With No Metastasis in Six Years From to Nodular Lesions.
J Med Cases
January 2025
Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama City 700-8558, Japan.
Conjunctival malignant melanoma is extremely rare, with no standard of care established at moment. Here we report a 65-year-old woman, as a hepatitis B virus (HBV) carrier, who presented concurrently a liver mass and lower bulbar conjunctival pigmented lesions in the right eye. Needle liver biopsy and excisional conjunctival biopsy showed hepatocellular carcinoma and conjunctival malignant melanoma , respectively.
View Article and Find Full Text PDFA Narrative Review of Molecular, Immunohistochemical and In-Situ Techniques in Dermatopathology.
Br J Biomed Sci
January 2025
St. John's Dermatopathology Laboratory, Synnovis Analytics, St. Thomas' Hospital, London, United Kingdom.
Article Synopsis
- Skin disorders are a major global health issue, affecting millions and requiring improved understanding and treatment approaches.
- Recent advancements in molecular techniques, like PCR and next-generation sequencing, have enhanced our ability to diagnose and treat these disorders accurately and effectively.
- These technologies allow for precise identification of infectious agents, genetic mutations, and gene expression patterns, leading to personalized therapies and better management of conditions like skin cancer and infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!